Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration von Çelik, Uğur, Aydemir, Ertuğrul H, Engin, Burhan, Oba, Muazzez Ç, Yılmaz, Mesut, Meşe, Şermin Güven

Volltext

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma von Yilmaz, Mesut, Güven Meşe, Şermin

Volltext

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAF V600E -mutant metastatic melanoma von Yilmaz, Mesut, Güven Meşe, Şermin

Volltext

Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients von Yilmaz, Mesut, Guven Mese, Sermin

Volltext

Nivolumab-induced lichen planus von Yilmaz, Mesut, Mese, Sermin Guven, Celik, Ugur

Volltext

An advanced c-MET-amplified NSCLC patient that was treated with crizotinib von Yilmaz, Mesut, Mese, Sermin Guven, Cil, Ibrahim, Zirtiloglu, Alisan

Volltext